Centenara Labs brings together an exceptional global team, representing the world`s most prestigious medical and scientific institutions. We leverage a deep understanding of the biology of aging, with decades of proven experience at the frontier of drug discovery.


Christian Angermayer is an entrepreneur and investor as well as the founder of Apeiron Investment Group, his family office and asset management business. Apeiron focuses on Life Sciences, FinTech/InsurTech/PropTech & Crypto and DeepTech (e.g. SpaceTech, AI, etc.). In these sectors, Apeiron has a deep experience and a proven track record of more than 20 years.

Shannon Thyme Klinger is the Chief Legal Officer of Moderna, Inc. She has over 25 years of global leadership experience in the pharmaceutical industry across a wide range of functional areas, including legal, compliance, IP, licensing, mergers and acquisitions, public/government affairs, communications, risk management, quality, and regulatory affairs. She is a recognized thought leader in the areas of ESG, social intrapreneurship, and diversity, equity, and inclusion.
Throughout her career, she has focused on driving long-term business performance and building trust with society, including ensuring access to medicine, protecting innovation with intellectual property, and championing the responsible use of data.
Ms. Klinger currently serves as a member of the board of directors of the Association of Corporate Counsel and has previously served on the board of directors of the SIX Group and Rafael Holdings Inc.

As an independent public board member & chair (NASDAQ & CSX) Teresa DeLuca’s experience includes a SPAC transition, an IPO and replacing private equity firms. Further, as a founding chair for three separate committees (compensation, compliance and governance committees), she has created both structure and process while leading strategic and operational discussions.
Teresa DeLuca’s most recent public board seat, at 180 Life Sciences (NASDAQ: ATNF), where she serves as chair of Compensation Committee and member of Nominating Governance Committee, was from a SPAC transaction.
Teresa DeLuca is an advocate for strong board governance and she has demonstrated that commitment through continued professional education and maintaining good standing with the National Association of Corporate Directors (NACD) as a Board Leadership Fellow, Master Level.
Teresa DeLuca has passed the NACD’s “Directorship Certified” (NACD.DC) examination, earned the Carnegie Mellon Cybersecurity certificate and was named “2020 Director to Watch” in the Directors & Board Annual Report.

Etienne’s career spans over 25 years of entrepreneurship and financing in the Healthcare (Biotech and Medtech) and IT spaces. Etienne has successfully led more than successful 100 fundraisings in those spaces, all across Europe and the USA, including both private and public (IPO & follow-on) transactions. His leadership record includes being CEO of such companies as GenyMobile SAS and Inc, Biom’up SA and Alganys Ltd. Etienne’s experience also includes securing medical products approvals through FDA, EMA and TGA, as well as their subsequent launches on 3 continents. Also a very active investor, Etienne has notably written their first cheques to leading start-up studios and company builders (iBionext, etc) in Europe. As a devoted supporter of the Live Arts, he sits on the board of such established institutions as the Paris Opera Fund, or the Los Angeles Dance Project.

Aksana brings 10+ years of experience in the life science and healthcare industry, including early-stage business development, company building, and venture. At Rejuveron she oversees investments, deal sourcing and contributes to strategic expansion of our portfolio companies.

Caleb has over 20 years of international finance experience across multiple sectors and geographies. He has worked in CFO roles as well as investment banking and over the course of his career has executed ~$30 billion of equity and debt financings spanning numerous industries and markets (US, Europe, and Asia).

Aaron is a seasoned investor and operator of life science companies. He has provided expert counsel on numerous types of capital market issuances, emerging markets debt, covered bonds, high yield and restructurings. He has lead investor relations experience across several portfolios.

Estela is a Venture Developer at Rejuveron Life Sciences AG, specializing in the biotech and longevity sectors. She plays a key role in identifying and evaluating new opportunities, conducting thorough due diligence, and providing scientific assessments to inform strategic planning. With a strong foundation in neuroscience and business development, she actively contributes to financial strategies, event coordination, and leading comprehensive market analyses, while maintaining a strong network within the industry.

With over a decade of executive assistance experience, Lisa has transitioned into the role of Operations Manager, bringing her expertise in optimizing efficiency and streamlining processes. Fluent in English, German, and French, she excels in fostering collaboration across teams. Lisa’s focus now includes overseeing operations, ensuring smooth workflows, and driving organizational success in dynamic startup environments.

Etienne’s career spans over 25 years of entrepreneurship and financing in the Healthcare (Biotech and Medtech) and IT spaces. Etienne has successfully led more than successful 100 fundraisings in those spaces, all across Europe and the USA, including both private and public (IPO & follow-on) transactions. His leadership record includes being CEO of such companies as GenyMobile SAS and Inc, Biom’up SA and Alganys Ltd. Etienne’s experience also includes securing medical products approvals through FDA, EMA and TGA, as well as their subsequent launches on 3 continents. Also a very active investor, Etienne has notably written their first cheques to leading start-up studios and company builders (iBionext, etc) in Europe. As a devoted supporter of the Live Arts, he sits on the board of such established institutions as the Paris Opera Fund, or the Los Angeles Dance Project.

Aksana brings 10+ years of experience in the life science and healthcare industry, including early-stage business development, company building, and venture. At Rejuveron she oversees investments, deal sourcing and contributes to strategic expansion of our portfolio companies.

Caleb has over 20 years of international finance experience across multiple sectors and geographies. He has worked in CFO roles as well as investment banking and over the course of his career has executed ~$30 billion of equity and debt financings spanning numerous industries and markets (US, Europe, and Asia).

Aaron is a seasoned investor and operator of life science companies. He has provided expert counsel on numerous types of capital market issuances, emerging markets debt, covered bonds, high yield and restructurings. He has lead investor relations experience across several portfolios.

Christian Angermayer is an entrepreneur and investor as well as the founder of Apeiron Investment Group, his family office and asset management business. Apeiron focuses on Life Sciences, FinTech/InsurTech/PropTech & Crypto and DeepTech (e.g. SpaceTech, AI, etc.). In these sectors, Apeiron has a deep experience and a proven track record of more than 20 years.

Aksana brings 10+ years of experience in the life science and healthcare industry, including early-stage business development, company building, and venture. At Rejuveron she oversees investments, deal sourcing and contributes to strategic expansion of our portfolio companies.

Shannon Thyme Klinger is the Chief Legal Officer of Moderna, Inc. She has over 25 years of global leadership experience in the pharmaceutical industry across a wide range of functional areas, including legal, compliance, IP, licensing, mergers and acquisitions, public/government affairs, communications, risk management, quality, and regulatory affairs. She is a recognized thought leader in the areas of ESG, social intrapreneurship, and diversity, equity, and inclusion.
Throughout her career, she has focused on driving long-term business performance and building trust with society, including ensuring access to medicine, protecting innovation with intellectual property, and championing the responsible use of data.
Ms. Klinger currently serves as a member of the board of directors of the Association of Corporate Counsel and has previously served on the board of directors of the SIX Group and Rafael Holdings Inc.

As an independent public board member & chair (NASDAQ & CSX) Teresa DeLuca’s experience includes a SPAC transition, an IPO and replacing private equity firms. Further, as a founding chair for three separate committees (compensation, compliance and governance committees), she has created both structure and process while leading strategic and operational discussions.
Teresa DeLuca’s most recent public board seat, at 180 Life Sciences (NASDAQ: ATNF), where she serves as chair of Compensation Committee and member of Nominating Governance Committee, was from a SPAC transaction.
Teresa DeLuca is an advocate for strong board governance and she has demonstrated that commitment through continued professional education and maintaining good standing with the National Association of Corporate Directors (NACD) as a Board Leadership Fellow, Master Level.
Teresa DeLuca has passed the NACD’s “Directorship Certified” (NACD.DC) examination, earned the Carnegie Mellon Cybersecurity certificate and was named “2020 Director to Watch” in the Directors & Board Annual Report.

- CEO of Optispan and Affiliate Professor of Oral Health at the University of Washington
- Founding Director of the University of Washington Healthy Aging and Longevity Research Institute
- Research focused on understanding the biological mechanisms of aging

- Former President and CEO of the Buck Institute for Research on Aging
- Director of the Centre for Healthy Ageing and Distinguished Professor in Biochemistry and Physiology at the Yong Loo Lin School of Medicine at National University Singapore

- Professor at the University of Paris Cité
- Renowned for discovering that mitochondrial membrane permeabilization is a key step in programmed cell death, contributing to immunogenic antineoplastic treatments.
Our Corporate Values:
Make therapies happen
We create therapies and technologies by translating breakthrough discoveries into longevity drugs with the aim to improve healthy aging and prolong lifespan. We pursue pioneering scientific fields and make courageous and informed choices to create novel medical treatment paradigms. We follow our informed decisions to explore new scientific grounds, even though it might be on an unconventional path.
Make it sustainable
We believe that living longer only has a purpose if the way we conduct our research also simultaneously contributes to the well-being of our planet. We’re also aware of the fact that drug discovery and development is a team effort – we hence support and encourage each other to open new doors and explore unchartered territory.
Make yourself curious
We believe in staying modest, embracing scientific progress in related fields and beyond, while continuously opening new doors to discover new ways of therapeutic interventions. We accept and learn from others. Our prepared minds are ready to endorse serendipitous discoveries.
Our Vision for the Future:
